Vertex Pharmaceuticals Inc
VRTX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News
$VRTX is featured in our Rob Bresnahan strategy.
All StrategiesIncome
Balance Sheet
Cash Flow
Revenue Breakdown
Recent trades of VRTX by members of U.S. Congress
VRTX Stock Insider Trading Activity
Follow @QuiverQuant for major insider updates
---
Closing Price
Purchase
Sale
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
VRTX Stock Institutional Owners
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
VRTX Derivatives Institutional Owners
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in VRTX holdings by institutional investors
Quarterly net insider trading by VRTX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Backtest Start Date
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Subscribe to Quiver Premium for insider trading alerts
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$1,200,000 Jul 16, 2026 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations Veterans Defense District of Columbia
-
$1,140,000 Apr 17, 2026 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations Trade (domestic/foreign) Veterans Defense
-
$1,110,000 Jan 13, 2026 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations Trade (domestic/foreign) Pharmacy Veterans
-
$1,110,000 Oct 14, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations Trade (domestic/foreign) Pharmacy
-
$1,140,000 Oct 09, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations Trade (domestic/foreign) Pharmacy
-
$1,600,000 Apr 18, 2025 Issue: Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations Health Issues
-
$970,000 Jan 17, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$1,000,000 Oct 18, 2024 Issue: Budget/Appropriations Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$980,000 Jul 15, 2024 Issue: Medicare/Medicaid Health Issues
-
$80,000 Apr 09, 2024 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Budget/Appropriations
-
$60,000 Jan 22, 2024 Issue: Health Issues Medicare/Medicaid
-
$50,000 Jan 22, 2024 Issue: Health Issues
-
$30,000 Jan 20, 2024 Issue: Budget/Appropriations Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
-
$80,000 Jan 12, 2024 Issue: Health Issues Medicare/Medicaid
-
$890,000 Oct 19, 2023 Issue: Medicare/Medicaid Budget/Appropriations Taxation/Internal Revenue Code Health Issues
-
$630,000 Jul 19, 2023 Issue: Medicare/Medicaid Budget/Appropriations Taxation/Internal Revenue Code Health Issues
-
$370,000 Jan 18, 2023 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Taxation/Internal Revenue Code Health Issues
-
$710,000 Oct 14, 2022 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Taxation/Internal Revenue Code Health Issues
-
$520,000 Jul 19, 2022 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$520,000 Apr 20, 2022 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$630,000 Jan 20, 2022 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$450,000 Oct 20, 2021 Issue: Health Issues Taxation/Internal Revenue Code Budget/Appropriations Medicare/Medicaid
-
$420,000 Jul 19, 2021 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$570,000 May 21, 2021 Issue: Health Issues Medicare/Medicaid
-
$410,000 Apr 19, 2021 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$380,000 Oct 20, 2020 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$380,000 Jul 20, 2020 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$390,000 Apr 20, 2020 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$530,000 Jan 21, 2020 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$310,000 Oct 21, 2019 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$310,000 Jul 22, 2019 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$320,000 Apr 19, 2019 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$450,000 Jan 21, 2019 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$340,000 Oct 19, 2018 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$350,000 Jul 18, 2018 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$350,000 Apr 19, 2018 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$340,000 Jan 19, 2018 Issue: Medicare/Medicaid Taxation/Internal Revenue Code Health Issues
-
$340,000 Oct 19, 2017 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$560,000 Jul 20, 2017 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$450,000 Apr 20, 2017 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$340,000 Jan 20, 2017 Issue: Medicare/Medicaid Taxation/Internal Revenue Code Health Issues
-
$350,000 Oct 20, 2016 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$440,000 Jul 20, 2016 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$210,000 Apr 20, 2016 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$350,000 Jan 19, 2016 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$330,000 Oct 20, 2015 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$300,000 Jul 20, 2015 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$380,000 Apr 20, 2015 Issue: Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark Medicare/Medicaid
-
$210,000 Jan 19, 2015 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$280,000 Oct 16, 2014 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$480,000 Jul 21, 2014 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$190,000 Apr 21, 2014 Issue: Medicare/Medicaid Taxation/Internal Revenue Code Copyright/Patent/Trademark Health Issues
-
$210,000 Jan 20, 2014 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$210,000 Oct 21, 2013 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$460,000 Jul 18, 2013 Issue: Health Issues
-
$300,000 Apr 22, 2013 Issue: Health Issues
-
$260,000 Jan 22, 2013 Issue: Budget/Appropriations Health Issues
-
$250,000 Oct 19, 2012 Issue: Health Issues Budget/Appropriations
-
$360,000 Jul 20, 2012 Issue: Budget/Appropriations Health Issues
-
$490,000 Apr 20, 2012 Issue: Health Issues Budget/Appropriations
-
$480,000 Jan 19, 2012 Issue: Health Issues Budget/Appropriations
-
$360,000 Oct 20, 2011 Issue: Health Issues Budget/Appropriations
-
$450,000 Jul 19, 2011 Issue: Health Issues
-
$460,000 Apr 20, 2011 Issue: Health Issues
-
$140,000 Jan 19, 2011 Issue: Health Issues
-
$370,000 Oct 20, 2010 Issue: Health Issues
-
$170,000 Jul 20, 2010 Issue: Health Issues
-
$300,000 Apr 20, 2010 Issue: Health Issues
-
$120,000 Jan 20, 2010 Issue: Health Issues
-
$130,000 Oct 20, 2009 Issue: Health Issues
-
$130,000 Jul 20, 2009 Issue: Health Issues
-
$180,000 Apr 20, 2009 Issue: Health Issues
-
$100,000 Jan 21, 2009 Issue: Health Issues
-
$120,000 Oct 20, 2008 Issue: Health Issues
-
$80,000 Jul 21, 2008 Issue: Health Issues
-
$80,000 Apr 21, 2008 Issue: Science/Technology Medical/Disease Research/Clinical Labs Medicare/Medicaid Copyright/Patent/Trademark Budget/Appropriations Health Issues
Former government officials who have lobbied for VRTX
70 former government officials from 49 congressional offices at 16 lobbying firms have lobbied for VRTX, most recently Aug 03, 2026.
-
Laura Friedel Senate Leg. Asst., Sen. Zell Miller, Leg. Dir., Sen. Richard Shelby, Clerk, Staff Dir., Sen. Appropriations Committee -
Parick Carroll House New Leg Asst. Rep. Ray LaHood, Leg Dir. Rep. Kevin Yoder, PSM Senate Appropriations Cmte. -
Margaret Joseph Senate CoS for Sen. Kyrsten Sinema, CoS for Rep. Kyrsten Sinema, CoS for Rep. Bobby Bright, CoS for Rep. Jim Matheson, Clerk for House Rules Cmte. -
Peter Fise Congress Health Counsel for Sen. Cmte on Finance, Health Counsel for Sen. Jeanne Shaheen, Staff Assistant for House Cmte on Oversight & Government Reform
-
Raissa Downs Senate Prin. Dep. Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg. - HHS; Staff Dir., Sub. Cmte. on Employment, Sen. HELP Cmte.
-
Jennifer Young Congress Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg. - HHS; Cmte. Staff, House Cmte. on Ways and Means; Cmte. Staff, Sen. Cmte. on Finance
-
Charlotte Ivancic Senate Legislative Counsel, Senator Jim DeMint; Health Counsel, Majority Leader Bill Frist; Counsel and Budget Analyst, House Budget Committee; Asst. to the Speaker for Policy, Speaker John Boehner -
Pamela Smith Senate Leg. Dir., Sen. Tom Harkin; Dep. Staff Dir., Senate HELP Cmte; Staff Dir., Senate HELP Cmte; Counselor to the Asst. AG, Civil Div., Dept of Justice; Spec Counsel, Ofc of Leg. Affairs, Dept of Justice; Counsel and LA, Senator Carol Moseley-Braun
VRTX Estimated quarterly lobbying spending
VRTX Revenue by Segment or Geography
By Segment
By Geography
VRTX Income Statement
VRTX Balance Sheet
VRTX Cash Flow
U.S. Patents
New VRTX patent grants
-
Patent Title: Indole derivatives as cftr modulators Jun. 10, 2025
-
Patent Title: Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto Apr. 25, 2023
-
Patent Title: Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto Oct. 20, 2020
-
Patent Title: Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto Mar. 26, 2019
-
Patent Title: Prodrug of an ice inhibitor Jun. 12, 2018
-
Patent Title: Substituted benzooxadiazole dna-pk inhibitors Jun. 05, 2018
-
Patent Title: Modulators of atp-binding cassette transporters May. 22, 2018
-
Patent Title: Mannose derivatives for treating bacterial infections May. 08, 2018
-
Patent Title: Solid forms of n[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Apr. 03, 2018
-
Patent Title: Dna-pk inhibitors and uses thereof Mar. 27, 2018
-
Patent Title: Inhibitors of influenza viruses replication Mar. 06, 2018
-
Patent Title: Mannose derivatives for treating bacterial infections Feb. 13, 2018
-
Patent Title: Dna-pk inhibitors for treatment of cancer Jan. 30, 2018
-
Patent Title: Processes for making compounds useful as inhibitors of atr kinase Jan. 09, 2018
-
Patent Title: Modulators of cystic fibrosis transmembrane conductance regulator Jan. 02, 2018
-
Patent Title: Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid Dec. 12, 2017
-
Patent Title: Prodrugs of pyridone amides useful as modulators of sodium channels Nov. 28, 2017
-
Patent Title: Inhibitors of influenza viruses replication Nov. 07, 2017
-
Patent Title: Method for measuring atr inhibition mediated increases in dna damage Oct. 17, 2017
-
Patent Title: Substituted quinolines as modulators of sodium channels Oct. 10, 2017
-
Patent Title: Modulators of cystic fibrosis transmembrane conductance regulator Oct. 10, 2017
-
Patent Title: Processes for producing cycloalkylcarboxamido-pyridine benzoic acids Oct. 03, 2017
-
Patent Title: Inhibitors of influenza viruses replication Sep. 26, 2017
-
Patent Title: Modulators of atp-binding cassette transporters Sep. 12, 2017
-
Patent Title: Pyridone amides as modulators of sodium channels Sep. 12, 2017
-
Patent Title: Heteroaryl derivatives as cftr modulators Sep. 05, 2017
-
Patent Title: Process for making modulators of cystic fibrosis transmembrane conductance regulator Sep. 05, 2017
-
Patent Title: Azaindole derivatives as cftr modulators Aug. 15, 2017
-
Patent Title: Modulators of cftr Aug. 08, 2017
-
Patent Title: Compounds useful as inhibitors of atr kinase Aug. 01, 2017
-
Patent Title: Substituted pyrazines as atr kinase inhibitors Jul. 11, 2017
-
Patent Title: Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator Jul. 11, 2017
-
Patent Title: Isoindolinone inhibitors of phosphatidylinositol 3-kinase Jun. 13, 2017
-
Patent Title: Compounds useful as inhibitors of atr kinase Jun. 06, 2017
-
Patent Title: Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Jun. 06, 2017
-
Patent Title: Compounds useful as inhibitors of atr kinase May. 30, 2017
-
Patent Title: Compounds useful as inhibitors of atr kinase May. 16, 2017
-
Patent Title: Compounds useful as inhibitors of atr kinase Apr. 25, 2017
-
Patent Title: Mannose derivatives for treating bacterial infections Mar. 21, 2017
-
Patent Title: Dna-pk inhibitors Mar. 14, 2017
-
Patent Title: Modulators of atp-binding cassette transporters Jan. 24, 2017
-
Patent Title: Methods of regioselective synthesis of 2,4-disubstituted pyrimidines Jan. 03, 2017
-
Patent Title: Modulators of atp-binding cassette transporters Dec. 20, 2016
-
Patent Title: Inhibitors of influenza viruses replication Dec. 13, 2016
-
Patent Title: Substituted spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]s as modulators of ion channels Dec. 06, 2016
-
Patent Title: Heteroaryl derivatives as cftr modulators Nov. 29, 2016
-
Patent Title: Compounds useful as inhibitors of indoleamine 2,3-dioxygenase Nov. 22, 2016
-
Patent Title: Prodrug of an ice inhibitor Nov. 08, 2016
-
Patent Title: Prodrugs of pyridone amides useful as modulators of sodium channels Oct. 11, 2016
-
Patent Title: Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto Aug. 09, 2016
Government Contracts
Federal grants, loans, and purchases
Government Contracts
Estimated quarterly amount awarded to VRTX from public contracts
VRTX News
Recent insights relating to VRTX
CNBC Recommendations
Recent picks made for VRTX stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in VRTX
VRTX Analyst Ratings
VRTX Stock Forecasts
...
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
VRTX Analyst Forecasts
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
Frequently Asked Questions
- Is $VRTX stock a Buy, Sell, or Hold?
- What is the price target for $VRTX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
VRTX Top Shareholders
|
Shareholder
|
Shares Held
|
|---|
Frequently Asked Questions
- Who owns $VRTX stock?
- Who owns the most shares of $VRTX stock?
- What funds own $VRTX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
VRTX Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view VRTX Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
About VRTX
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
- Address Boston, MA
- Market Cap 130.9 billion
- Employees 6,400
- Industrial Classification Pharmaceutical Preparations
Vertex Pharmaceuticals Inc (VRTX) Historical Stock Prices
Vertex Pharmaceuticals Inc (VRTX) closed at $516.34 on September 23, 2026. Over the past year its adjusted close ranged from $376.62 to $557.96. Daily prices go back to January 2, 2014, 3,199 trading days in all.
- 1 month-5.71%
- 3 months+8.66%
- Year to date+13.89%
- 1 year+35.98%
- 3 years+47.72%
- 5 years+181.22%
- Max+599.36%
See every congressional and insider trade on the VRTX price chart
Quiver Premium charts VRTX's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | 515.60 | 525.43 | 509.56 | 516.34 | 516.34 | 1,214,098 |
| Sep 22, 2026 | 521.69 | 525.97 | 508.14 | 514.99 | 514.99 | 1,386,645 |
| Sep 21, 2026 | 506.85 | 514.10 | 501.01 | 510.72 | 510.72 | 906,681 |
| Sep 18, 2026 | 516.34 | 518.10 | 505.01 | 508.34 | 508.34 | 2,434,832 |
| Sep 17, 2026 | 518.35 | 519.07 | 510.19 | 516.34 | 516.34 | 900,049 |
| Sep 16, 2026 | 513.80 | 517.95 | 511.35 | 513.26 | 513.26 | 638,512 |
| Sep 15, 2026 | 519.94 | 519.94 | 511.00 | 514.63 | 514.63 | 824,890 |
| Sep 14, 2026 | 522.17 | 525.29 | 514.65 | 519.51 | 519.51 | 837,109 |
| Sep 11, 2026 | 522.10 | 522.10 | 511.81 | 515.44 | 515.44 | 875,635 |
| Sep 10, 2026 | 519.13 | 522.60 | 514.32 | 514.56 | 514.56 | 815,171 |
| Sep 9, 2026 | 524.00 | 528.16 | 520.08 | 521.12 | 521.12 | 958,510 |
| Sep 8, 2026 | 529.64 | 535.00 | 520.20 | 528.90 | 528.90 | 1,121,470 |
| Sep 4, 2026 | 549.50 | 556.99 | 544.48 | 546.12 | 546.12 | 803,524 |
| Sep 3, 2026 | 559.00 | 560.25 | 551.61 | 557.96 | 557.96 | 800,963 |
| Sep 2, 2026 | 552.42 | 558.36 | 549.07 | 556.75 | 556.75 | 1,734,757 |
| Sep 1, 2026 | 548.60 | 551.40 | 545.08 | 547.65 | 547.65 | 735,119 |
| Aug 31, 2026 | 535.38 | 546.84 | 532.23 | 544.52 | 544.52 | 1,198,447 |
| Aug 28, 2026 | 547.09 | 549.57 | 540.08 | 541.69 | 541.69 | 886,917 |
| Aug 27, 2026 | 540.08 | 550.83 | 540.08 | 547.55 | 547.55 | 844,619 |
| Aug 26, 2026 | 549.84 | 553.47 | 546.24 | 547.29 | 547.29 | 834,375 |
| Aug 25, 2026 | 545.53 | 555.69 | 543.75 | 552.85 | 552.85 | 775,039 |
| Aug 24, 2026 | 548.98 | 550.62 | 542.42 | 547.59 | 547.59 | 767,491 |
| Aug 21, 2026 | 545.10 | 555.32 | 540.70 | 548.05 | 548.05 | 1,074,991 |
| Aug 20, 2026 | 543.78 | 548.99 | 538.27 | 540.26 | 540.26 | 1,062,465 |
| Aug 19, 2026 | 537.47 | 553.69 | 532.55 | 552.06 | 552.06 | 1,437,713 |
| Aug 18, 2026 | 520.00 | 533.78 | 517.34 | 528.19 | 528.19 | 1,497,081 |
| Aug 17, 2026 | 503.87 | 517.84 | 502.53 | 515.55 | 515.55 | 1,111,401 |
| Aug 14, 2026 | 511.41 | 513.64 | 502.29 | 505.75 | 505.75 | 1,130,504 |
| Aug 13, 2026 | 528.68 | 529.00 | 515.74 | 516.44 | 516.44 | 863,530 |
| Aug 12, 2026 | 527.00 | 531.22 | 520.08 | 525.73 | 525.73 | 1,047,017 |
| Aug 11, 2026 | 525.02 | 532.23 | 522.01 | 529.65 | 529.65 | 1,065,447 |
| Aug 10, 2026 | 539.50 | 546.17 | 519.82 | 523.91 | 523.91 | 2,682,319 |
| Aug 7, 2026 | 487.11 | 497.39 | 482.10 | 496.07 | 496.07 | 992,491 |
| Aug 6, 2026 | 490.91 | 492.40 | 480.86 | 484.03 | 484.03 | 1,015,131 |
| Aug 5, 2026 | 487.52 | 491.95 | 479.02 | 484.83 | 484.83 | 1,383,067 |
| Aug 4, 2026 | 471.29 | 488.04 | 465.51 | 478.70 | 478.70 | 2,026,378 |
| Aug 3, 2026 | 480.00 | 483.36 | 468.14 | 470.72 | 470.72 | 1,510,456 |
| Jul 31, 2026 | 480.67 | 480.67 | 469.87 | 477.10 | 477.10 | 957,709 |
| Jul 30, 2026 | 474.10 | 482.14 | 470.54 | 481.70 | 481.70 | 1,249,350 |
| Jul 29, 2026 | 492.67 | 492.99 | 481.91 | 483.33 | 483.33 | 1,451,920 |
| Jul 28, 2026 | 483.13 | 493.61 | 482.86 | 490.39 | 490.39 | 1,700,871 |
| Jul 27, 2026 | 479.27 | 487.21 | 477.99 | 479.00 | 479.00 | 1,631,004 |
| Jul 24, 2026 | 476.05 | 484.00 | 472.57 | 477.36 | 477.36 | 1,254,156 |
| Jul 23, 2026 | 467.09 | 477.68 | 465.00 | 473.09 | 473.09 | 1,306,125 |
| Jul 22, 2026 | 482.32 | 483.66 | 471.58 | 472.57 | 472.57 | 1,289,189 |
| Jul 21, 2026 | 478.56 | 484.99 | 473.56 | 482.00 | 482.00 | 1,107,414 |
| Jul 20, 2026 | 485.65 | 491.23 | 478.48 | 480.50 | 480.50 | 1,101,762 |
| Jul 17, 2026 | 483.51 | 496.69 | 481.98 | 485.65 | 485.65 | 1,568,122 |
| Jul 16, 2026 | 480.00 | 487.30 | 476.25 | 486.03 | 486.03 | 1,370,959 |
| Jul 15, 2026 | 472.15 | 480.96 | 469.60 | 477.08 | 477.08 | 1,192,070 |
| Jul 14, 2026 | 481.29 | 481.29 | 473.18 | 476.31 | 476.31 | 1,093,659 |
| Jul 13, 2026 | 486.18 | 486.18 | 474.71 | 480.25 | 480.25 | 1,153,856 |
| Jul 10, 2026 | 498.15 | 498.91 | 484.33 | 485.39 | 485.39 | 1,430,390 |
| Jul 9, 2026 | 495.58 | 500.77 | 482.11 | 496.50 | 496.50 | 2,107,282 |
| Jul 8, 2026 | 523.04 | 525.81 | 498.14 | 498.43 | 498.43 | 2,287,222 |
| Jul 7, 2026 | 530.00 | 533.67 | 512.77 | 522.25 | 522.25 | 2,292,906 |
| Jul 6, 2026 | 526.66 | 529.99 | 512.34 | 529.59 | 529.59 | 1,515,703 |
| Jul 2, 2026 | 503.76 | 529.14 | 501.53 | 528.04 | 528.04 | 1,855,943 |
| Jul 1, 2026 | 502.71 | 502.71 | 494.80 | 498.01 | 498.01 | 1,444,535 |
| Jun 30, 2026 | 500.49 | 500.99 | 489.62 | 496.73 | 496.73 | 1,738,335 |
| Jun 29, 2026 | 495.83 | 499.87 | 487.62 | 499.65 | 499.65 | 2,055,780 |
| Jun 26, 2026 | 482.50 | 503.89 | 482.20 | 491.34 | 491.34 | 8,693,047 |
| Jun 25, 2026 | 475.11 | 486.49 | 473.50 | 480.18 | 480.18 | 1,522,567 |
| Jun 24, 2026 | 471.38 | 480.86 | 469.93 | 475.20 | 475.20 | 1,549,953 |
| Jun 23, 2026 | 469.67 | 470.82 | 463.75 | 468.42 | 468.42 | 1,204,019 |
| Jun 22, 2026 | 455.65 | 468.18 | 453.21 | 466.79 | 466.79 | 2,034,573 |
| Jun 18, 2026 | 462.17 | 464.98 | 450.39 | 451.63 | 451.63 | 2,993,021 |
| Jun 17, 2026 | 449.67 | 464.31 | 447.54 | 458.99 | 458.99 | 1,524,291 |
| Jun 16, 2026 | 452.82 | 454.55 | 444.21 | 453.17 | 453.17 | 1,486,576 |
| Jun 15, 2026 | 446.69 | 453.68 | 439.50 | 450.46 | 450.46 | 1,482,949 |
| Jun 12, 2026 | 440.02 | 447.70 | 440.02 | 444.93 | 444.93 | 924,189 |
| Jun 11, 2026 | 437.51 | 445.78 | 435.21 | 445.04 | 445.04 | 1,233,868 |
| Jun 10, 2026 | 447.27 | 447.50 | 433.80 | 435.71 | 435.71 | 1,103,240 |
| Jun 9, 2026 | 447.02 | 449.50 | 440.90 | 445.77 | 445.77 | 871,497 |
| Jun 8, 2026 | 443.17 | 448.69 | 441.72 | 442.96 | 442.96 | 1,149,408 |
| Jun 5, 2026 | 445.61 | 453.16 | 443.86 | 446.83 | 446.83 | 1,530,180 |
| Jun 4, 2026 | 434.95 | 448.19 | 433.50 | 441.74 | 441.74 | 1,362,422 |
| Jun 3, 2026 | 420.63 | 429.01 | 420.01 | 428.34 | 428.34 | 1,564,384 |
| Jun 2, 2026 | 432.40 | 434.00 | 424.90 | 425.09 | 425.09 | 1,147,095 |
| Jun 1, 2026 | 439.91 | 443.54 | 433.26 | 438.40 | 438.40 | 1,115,281 |
| May 29, 2026 | 448.01 | 450.00 | 442.25 | 447.54 | 447.54 | 1,893,380 |
| May 28, 2026 | 434.08 | 449.29 | 434.08 | 447.97 | 447.97 | 1,358,231 |
| May 27, 2026 | 438.52 | 445.35 | 435.39 | 437.22 | 437.22 | 1,164,524 |
| May 26, 2026 | 437.99 | 441.99 | 433.79 | 435.93 | 435.93 | 865,853 |
| May 22, 2026 | 437.07 | 438.84 | 432.96 | 434.52 | 434.52 | 1,746,340 |
| May 21, 2026 | 429.36 | 434.76 | 426.01 | 433.54 | 433.54 | 1,395,240 |
| May 20, 2026 | 434.31 | 439.98 | 427.64 | 430.44 | 430.44 | 1,784,847 |
| May 19, 2026 | 436.79 | 444.32 | 433.15 | 434.31 | 434.31 | 1,219,660 |
| May 18, 2026 | 435.42 | 440.04 | 430.25 | 436.58 | 436.58 | 1,451,054 |
| May 15, 2026 | 453.45 | 453.45 | 435.86 | 436.95 | 436.95 | 1,288,893 |
| May 14, 2026 | 453.64 | 456.68 | 447.36 | 450.41 | 450.41 | 1,088,448 |
| May 13, 2026 | 446.47 | 455.32 | 444.26 | 453.06 | 453.06 | 1,194,366 |
| May 12, 2026 | 439.92 | 454.23 | 436.48 | 448.29 | 448.29 | 1,398,283 |
| May 11, 2026 | 429.50 | 442.15 | 428.50 | 435.17 | 435.17 | 1,264,201 |
| May 8, 2026 | 422.37 | 431.94 | 421.11 | 429.82 | 429.82 | 953,348 |
| May 7, 2026 | 425.13 | 429.61 | 423.59 | 425.00 | 425.00 | 1,112,655 |
| May 6, 2026 | 422.67 | 431.06 | 422.67 | 427.65 | 427.65 | 1,203,285 |
| May 5, 2026 | 431.99 | 433.94 | 412.27 | 424.36 | 424.36 | 1,906,343 |
| May 4, 2026 | 423.75 | 430.13 | 422.11 | 429.85 | 429.85 | 1,418,890 |
| May 1, 2026 | 425.02 | 427.38 | 421.54 | 423.92 | 423.92 | 796,985 |
| Apr 30, 2026 | 423.65 | 430.95 | 423.65 | 427.38 | 427.38 | 1,121,184 |
| Apr 29, 2026 | 424.44 | 426.72 | 419.71 | 423.24 | 423.24 | 1,059,477 |
| Apr 28, 2026 | 431.25 | 431.77 | 426.68 | 430.14 | 430.14 | 808,540 |
| Apr 27, 2026 | 427.01 | 434.07 | 425.87 | 426.01 | 426.01 | 967,041 |
| Apr 24, 2026 | 431.89 | 433.68 | 427.38 | 430.29 | 430.29 | 1,128,100 |
| Apr 23, 2026 | 440.71 | 442.04 | 433.81 | 435.10 | 435.10 | 777,645 |
| Apr 22, 2026 | 437.38 | 441.00 | 435.45 | 437.67 | 437.67 | 734,332 |
| Apr 21, 2026 | 437.12 | 440.32 | 429.65 | 436.59 | 436.59 | 986,971 |
| Apr 20, 2026 | 444.01 | 444.01 | 437.67 | 439.18 | 439.18 | 789,463 |
| Apr 17, 2026 | 441.55 | 443.90 | 437.58 | 441.20 | 441.20 | 1,025,319 |
| Apr 16, 2026 | 442.35 | 445.93 | 431.15 | 435.65 | 435.65 | 1,364,285 |
| Apr 15, 2026 | 444.15 | 447.82 | 437.19 | 441.70 | 441.70 | 1,459,489 |
| Apr 14, 2026 | 435.28 | 444.79 | 435.28 | 444.28 | 444.28 | 1,445,501 |
| Apr 13, 2026 | 434.17 | 445.11 | 433.68 | 440.05 | 440.05 | 1,004,739 |
| Apr 10, 2026 | 446.08 | 446.75 | 434.25 | 436.27 | 436.27 | 985,779 |
| Apr 9, 2026 | 439.77 | 447.00 | 436.35 | 446.78 | 446.78 | 1,040,964 |
| Apr 8, 2026 | 436.25 | 443.99 | 432.33 | 443.92 | 443.92 | 1,279,267 |
| Apr 7, 2026 | 435.50 | 435.50 | 425.26 | 431.86 | 431.86 | 1,029,161 |
| Apr 6, 2026 | 437.79 | 440.90 | 433.45 | 434.30 | 434.30 | 948,862 |
| Apr 2, 2026 | 447.55 | 449.62 | 436.56 | 438.71 | 438.71 | 1,244,992 |
| Apr 1, 2026 | 449.17 | 453.98 | 446.71 | 447.26 | 447.26 | 1,188,465 |
| Mar 31, 2026 | 443.43 | 448.35 | 442.08 | 446.54 | 446.54 | 1,624,941 |
| Mar 30, 2026 | 438.73 | 443.65 | 432.13 | 443.16 | 443.16 | 1,961,081 |
| Mar 27, 2026 | 450.95 | 452.00 | 431.01 | 433.07 | 433.07 | 1,915,620 |
| Mar 26, 2026 | 450.72 | 457.54 | 449.29 | 453.74 | 453.74 | 1,158,222 |
| Mar 25, 2026 | 449.14 | 459.37 | 449.14 | 454.97 | 454.97 | 1,200,057 |
| Mar 24, 2026 | 447.02 | 452.08 | 441.20 | 448.62 | 448.62 | 1,224,223 |
| Mar 23, 2026 | 458.42 | 463.78 | 450.97 | 451.24 | 451.24 | 1,152,213 |
| Mar 20, 2026 | 454.62 | 461.05 | 452.88 | 454.00 | 454.00 | 2,200,399 |
| Mar 19, 2026 | 454.50 | 459.45 | 449.75 | 458.05 | 458.05 | 1,300,074 |
| Mar 18, 2026 | 462.80 | 463.96 | 451.10 | 451.59 | 451.59 | 1,410,794 |
| Mar 17, 2026 | 468.40 | 468.45 | 461.50 | 462.49 | 462.49 | 1,512,976 |
| Mar 16, 2026 | 475.14 | 476.17 | 461.13 | 466.10 | 466.10 | 1,496,839 |
| Mar 13, 2026 | 481.79 | 486.66 | 469.08 | 469.34 | 469.34 | 1,097,554 |
| Mar 12, 2026 | 489.97 | 489.97 | 476.57 | 478.13 | 478.13 | 1,607,828 |
| Mar 11, 2026 | 497.88 | 499.50 | 488.79 | 492.38 | 492.38 | 2,062,729 |
| Mar 10, 2026 | 482.25 | 507.92 | 477.77 | 499.17 | 499.17 | 3,363,817 |
| Mar 9, 2026 | 455.59 | 461.26 | 450.78 | 460.87 | 460.87 | 1,179,887 |
| Mar 6, 2026 | 457.30 | 460.00 | 450.67 | 456.69 | 456.69 | 1,171,660 |
| Mar 5, 2026 | 476.64 | 480.00 | 457.00 | 460.82 | 460.82 | 1,111,965 |
| Mar 4, 2026 | 475.30 | 480.68 | 470.43 | 477.89 | 477.89 | 996,319 |
| Mar 3, 2026 | 478.95 | 484.10 | 471.58 | 474.27 | 474.27 | 1,055,962 |
| Mar 2, 2026 | 496.60 | 498.02 | 484.40 | 486.03 | 486.03 | 1,034,547 |
| Feb 27, 2026 | 480.31 | 497.80 | 479.75 | 496.83 | 496.83 | 1,782,950 |
| Feb 26, 2026 | 483.36 | 483.63 | 474.59 | 480.13 | 480.13 | 1,305,617 |
| Feb 25, 2026 | 486.35 | 492.28 | 481.71 | 483.05 | 483.05 | 820,976 |
| Feb 24, 2026 | 479.20 | 491.22 | 479.00 | 487.43 | 487.43 | 1,331,564 |
| Feb 23, 2026 | 475.08 | 487.60 | 475.08 | 481.01 | 481.01 | 1,241,196 |
| Feb 20, 2026 | 466.94 | 479.12 | 465.00 | 476.90 | 476.90 | 1,006,630 |
| Feb 19, 2026 | 469.83 | 472.24 | 463.00 | 469.27 | 469.27 | 1,165,802 |
| Feb 18, 2026 | 473.68 | 477.72 | 466.45 | 470.31 | 470.31 | 1,662,976 |
| Feb 17, 2026 | 489.46 | 494.05 | 473.45 | 477.32 | 477.32 | 1,721,420 |
| Feb 13, 2026 | 471.64 | 503.88 | 471.64 | 491.47 | 491.47 | 2,918,342 |
| Feb 12, 2026 | 462.00 | 469.00 | 460.00 | 465.02 | 465.02 | 1,818,938 |
| Feb 11, 2026 | 460.43 | 464.73 | 454.40 | 461.24 | 461.24 | 1,845,927 |
| Feb 10, 2026 | 469.83 | 474.57 | 462.24 | 463.48 | 463.48 | 2,127,907 |
| Feb 9, 2026 | 476.97 | 478.54 | 467.98 | 470.87 | 470.87 | 1,794,837 |
| Feb 6, 2026 | 459.69 | 478.28 | 459.00 | 477.92 | 477.92 | 1,621,655 |
| Feb 5, 2026 | 473.90 | 478.00 | 457.74 | 458.81 | 458.81 | 1,673,029 |
| Feb 4, 2026 | 470.49 | 478.72 | 467.10 | 470.52 | 470.52 | 1,362,563 |
| Feb 3, 2026 | 468.80 | 476.83 | 461.52 | 465.61 | 465.61 | 1,051,140 |
| Feb 2, 2026 | 466.79 | 473.74 | 464.01 | 472.01 | 472.01 | 759,711 |
| Jan 30, 2026 | 471.18 | 475.67 | 468.00 | 469.90 | 469.90 | 1,190,465 |
| Jan 29, 2026 | 479.03 | 484.35 | 473.86 | 475.68 | 475.68 | 1,498,282 |
| Jan 28, 2026 | 474.09 | 479.50 | 469.50 | 477.91 | 477.91 | 1,089,266 |
| Jan 27, 2026 | 476.80 | 485.00 | 470.49 | 474.17 | 474.17 | 1,631,944 |
| Jan 26, 2026 | 470.79 | 479.10 | 468.43 | 476.84 | 476.84 | 1,668,198 |
| Jan 23, 2026 | 465.23 | 470.34 | 462.74 | 468.41 | 468.41 | 1,330,042 |
| Jan 22, 2026 | 463.74 | 472.58 | 458.31 | 467.35 | 467.35 | 1,535,068 |
| Jan 21, 2026 | 440.54 | 465.14 | 439.91 | 461.14 | 461.14 | 2,289,638 |
| Jan 20, 2026 | 435.41 | 442.38 | 429.00 | 442.08 | 442.08 | 1,811,384 |
| Jan 16, 2026 | 440.46 | 445.77 | 437.46 | 441.36 | 441.36 | 2,047,432 |
| Jan 15, 2026 | 448.79 | 450.44 | 436.69 | 438.92 | 438.92 | 1,215,021 |
| Jan 14, 2026 | 454.58 | 455.03 | 446.01 | 449.53 | 449.53 | 1,295,520 |
| Jan 13, 2026 | 460.22 | 462.42 | 452.91 | 454.67 | 454.67 | 1,346,146 |
| Jan 12, 2026 | 461.07 | 464.59 | 454.54 | 460.59 | 460.59 | 1,350,714 |
| Jan 9, 2026 | 467.73 | 475.33 | 463.39 | 463.86 | 463.86 | 1,700,271 |
| Jan 8, 2026 | 481.50 | 485.69 | 465.28 | 469.68 | 469.68 | 2,115,157 |
| Jan 7, 2026 | 469.12 | 487.52 | 467.46 | 484.15 | 484.15 | 1,723,842 |
| Jan 6, 2026 | 454.85 | 471.28 | 453.69 | 468.38 | 468.38 | 2,078,373 |
| Jan 5, 2026 | 448.83 | 450.72 | 443.12 | 448.80 | 448.80 | 931,443 |
| Jan 2, 2026 | 454.34 | 455.99 | 448.52 | 452.13 | 452.13 | 825,333 |
| Dec 31, 2025 | 451.75 | 455.92 | 451.75 | 453.36 | 453.36 | 692,988 |
| Dec 30, 2025 | 456.83 | 458.36 | 453.40 | 453.74 | 453.74 | 686,179 |
| Dec 29, 2025 | 463.00 | 463.55 | 457.45 | 459.78 | 459.78 | 628,247 |
| Dec 26, 2025 | 462.67 | 463.65 | 460.86 | 462.90 | 462.90 | 388,095 |
| Dec 24, 2025 | 459.39 | 464.44 | 459.08 | 462.99 | 462.99 | 310,231 |
| Dec 23, 2025 | 460.44 | 461.49 | 457.04 | 459.21 | 459.21 | 768,534 |
| Dec 22, 2025 | 454.34 | 460.94 | 453.03 | 460.31 | 460.31 | 919,586 |
| Dec 19, 2025 | 446.86 | 460.40 | 445.51 | 456.20 | 456.20 | 5,558,133 |
| Dec 18, 2025 | 449.74 | 452.63 | 445.41 | 447.38 | 447.38 | 1,056,928 |
| Dec 17, 2025 | 453.83 | 456.05 | 447.31 | 449.52 | 449.52 | 1,349,824 |
| Dec 16, 2025 | 455.71 | 459.05 | 452.83 | 454.96 | 454.96 | 1,258,691 |
| Dec 15, 2025 | 454.28 | 456.46 | 449.48 | 455.71 | 455.71 | 1,337,358 |
| Dec 12, 2025 | 444.81 | 456.00 | 444.81 | 452.04 | 452.04 | 1,621,663 |
| Dec 11, 2025 | 445.65 | 448.33 | 442.07 | 445.93 | 445.93 | 1,178,366 |
| Dec 10, 2025 | 438.81 | 446.28 | 433.81 | 444.64 | 444.64 | 999,755 |
| Dec 9, 2025 | 442.55 | 448.28 | 436.49 | 437.01 | 437.01 | 989,612 |
| Dec 8, 2025 | 455.65 | 457.17 | 439.80 | 442.04 | 442.04 | 1,504,581 |
| Dec 5, 2025 | 457.78 | 462.00 | 454.45 | 455.48 | 455.48 | 911,424 |
| Dec 4, 2025 | 462.00 | 463.70 | 453.54 | 457.36 | 457.36 | 1,518,932 |
| Dec 3, 2025 | 440.31 | 463.85 | 439.35 | 463.13 | 463.13 | 2,542,611 |
| Dec 2, 2025 | 427.33 | 435.20 | 424.06 | 433.15 | 433.15 | 1,399,828 |
| Dec 1, 2025 | 431.92 | 434.00 | 423.45 | 425.60 | 425.60 | 1,174,298 |
| Nov 28, 2025 | 434.67 | 434.67 | 429.07 | 433.61 | 433.61 | 727,908 |
| Nov 26, 2025 | 432.43 | 433.32 | 428.07 | 432.17 | 432.17 | 1,152,077 |
| Nov 25, 2025 | 425.92 | 431.50 | 424.12 | 429.82 | 429.82 | 1,550,242 |
| Nov 24, 2025 | 426.23 | 432.55 | 423.87 | 424.00 | 424.00 | 2,222,954 |
| Nov 21, 2025 | 423.13 | 435.85 | 421.87 | 426.76 | 426.76 | 1,917,729 |
| Nov 20, 2025 | 420.84 | 431.13 | 420.00 | 422.32 | 422.32 | 1,189,330 |
| Nov 19, 2025 | 434.36 | 434.93 | 418.53 | 421.03 | 421.03 | 1,545,529 |
| Nov 18, 2025 | 434.00 | 437.79 | 430.15 | 435.52 | 435.52 | 1,084,330 |
| Nov 17, 2025 | 436.99 | 439.99 | 432.24 | 434.02 | 434.02 | 1,304,724 |
| Nov 14, 2025 | 440.02 | 442.22 | 433.67 | 437.15 | 437.15 | 1,264,988 |
| Nov 13, 2025 | 434.01 | 441.23 | 430.66 | 434.52 | 434.52 | 1,560,129 |
| Nov 12, 2025 | 429.69 | 435.94 | 425.46 | 434.19 | 434.19 | 1,365,360 |
| Nov 11, 2025 | 423.30 | 429.48 | 417.12 | 429.22 | 429.22 | 990,097 |
| Nov 10, 2025 | 412.38 | 422.23 | 410.50 | 421.20 | 421.20 | 1,494,401 |
| Nov 7, 2025 | 415.61 | 416.27 | 406.67 | 409.47 | 409.47 | 1,357,940 |
| Nov 6, 2025 | 414.10 | 424.25 | 410.29 | 416.25 | 416.25 | 1,332,003 |
| Nov 5, 2025 | 417.70 | 427.18 | 410.45 | 417.00 | 417.00 | 1,421,053 |
| Nov 4, 2025 | 418.55 | 430.71 | 403.16 | 421.67 | 421.67 | 2,365,549 |
| Nov 3, 2025 | 428.48 | 430.10 | 418.60 | 426.00 | 426.00 | 1,939,051 |
| Oct 31, 2025 | 416.28 | 426.96 | 415.76 | 425.57 | 425.57 | 1,499,268 |
| Oct 30, 2025 | 417.19 | 422.95 | 415.00 | 419.89 | 419.89 | 1,234,430 |
| Oct 29, 2025 | 418.02 | 422.98 | 415.77 | 417.21 | 417.21 | 1,325,187 |
| Oct 28, 2025 | 418.00 | 422.57 | 417.37 | 422.39 | 422.39 | 1,219,402 |
| Oct 27, 2025 | 422.00 | 423.61 | 418.76 | 420.17 | 420.17 | 1,261,917 |
| Oct 24, 2025 | 423.41 | 425.86 | 420.60 | 421.39 | 421.39 | 1,004,920 |
| Oct 23, 2025 | 427.85 | 432.76 | 421.26 | 422.63 | 422.63 | 1,760,904 |
| Oct 22, 2025 | 426.27 | 431.81 | 421.94 | 426.44 | 426.44 | 1,697,244 |
| Oct 21, 2025 | 417.57 | 426.97 | 417.57 | 426.27 | 426.27 | 1,075,953 |
| Oct 20, 2025 | 418.17 | 420.50 | 414.52 | 419.10 | 419.10 | 1,083,498 |
| Oct 17, 2025 | 407.36 | 419.37 | 406.76 | 416.81 | 416.81 | 1,054,386 |
| Oct 16, 2025 | 409.92 | 413.31 | 405.54 | 408.61 | 408.61 | 1,314,376 |
| Oct 15, 2025 | 412.17 | 413.57 | 407.05 | 407.90 | 407.90 | 1,273,273 |
| Oct 14, 2025 | 406.08 | 415.55 | 405.45 | 412.22 | 412.22 | 1,048,332 |
| Oct 13, 2025 | 404.21 | 409.47 | 402.58 | 407.37 | 407.37 | 880,933 |
| Oct 10, 2025 | 413.33 | 414.22 | 406.10 | 407.79 | 407.79 | 1,148,580 |
| Oct 9, 2025 | 419.31 | 421.01 | 414.28 | 414.86 | 414.86 | 880,586 |
| Oct 8, 2025 | 410.93 | 422.73 | 410.02 | 421.15 | 421.15 | 1,930,626 |
| Oct 7, 2025 | 402.84 | 413.29 | 400.86 | 410.28 | 410.28 | 1,589,483 |
| Oct 6, 2025 | 404.66 | 405.44 | 400.74 | 402.90 | 402.90 | 1,191,393 |
| Oct 3, 2025 | 411.72 | 411.91 | 403.04 | 403.30 | 403.30 | 1,315,986 |
| Oct 2, 2025 | 404.21 | 411.00 | 402.81 | 408.85 | 408.85 | 1,642,232 |
| Oct 1, 2025 | 393.62 | 407.50 | 392.50 | 404.21 | 404.21 | 1,995,641 |
| Sep 30, 2025 | 394.94 | 397.65 | 385.86 | 391.64 | 391.64 | 2,260,508 |
| Sep 29, 2025 | 386.88 | 399.10 | 384.39 | 395.31 | 395.31 | 2,082,433 |
| Sep 26, 2025 | 381.91 | 387.48 | 379.72 | 385.74 | 385.74 | 1,838,743 |
| Sep 25, 2025 | 383.20 | 387.48 | 377.02 | 381.87 | 381.87 | 2,635,422 |
| Sep 24, 2025 | 377.56 | 380.73 | 374.17 | 376.62 | 376.62 | 1,530,847 |
| Sep 23, 2025 | 381.59 | 383.50 | 376.00 | 379.72 | 379.72 | 1,568,917 |
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
Need daily prices for every ticker, in code?
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver API
Vertex Pharmaceuticals Inc Executive Compensation
We estimate that -- received a compensation of -- in --, making them the highest paid executive at VRTX, per a recent SEC DEF 14A filing. We estimate that the median employee at VERTEX PHARMACEUTICALS INC / MA is paid $245,708.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|